acetylcysteine has been researched along with Parkinson Disease, Secondary in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 10 (76.92) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdurasulova, IN; Ekimova, IV; Gazizova, AR; Klimenko, VM; Matsulevich, AV; Pastukhov, YF | 1 |
| Ekimova, IV; Plaksina, DV | 1 |
| Ekimova, IV; Guzhova, IV; Lapshina, KV; Pastukhov, YF; Plaksina, DV | 1 |
| Andressoo, JO; Härma, MA; Jakobson, M; Karalija, N; Kopra, J; Kumar, A; Kuure, S; Lilleväli, K; Lindahl, M; Marshall, P; Mijatovic, J; Ola, R; Palm, E; Panhelainen, A; Piepponen, TP; Porokuokka, LL; Pulkkinen, N; Saarma, M; Strömberg, I; Tekko, T; Varendi, K; Vilenius, C; Võikar, V | 1 |
| Chen, Y; Ding, Z; Jiang, Y; Ren, H; Su, Y; Wang, J; Wu, J; Yu, W | 1 |
| Biswas, S; Dutta, AK; Le, W; Li, C; Li, X | 1 |
| Inoue, H; Ito, H; Matsui, H; Takahashi, R; Takeda, S; Taniguchi, Y | 1 |
| Jankovic, J; Le, W; Li, C; Li, X; Xie, W; Zhu, W | 1 |
| Crum, WR; Johansson, SM; Modo, M; Vernon, AC | 1 |
| Chesnokova, AIu; Ekimova, IV; Iakimchuk, AA; Khudik, KA; Pastukhov, IuF; Romanova, IV | 1 |
| Belizaire, R; Björklund, LM; Isacson, O; Jenner, P; McNaught, KS; Olanow, CW | 1 |
| Baptiste, RJ; McNaught, KS; Mytilineou, C; Olanow, CW; Parnandi, A; Shashidharan, P; Yabut, J | 1 |
| Chae, HZ; Hwang, JY; Jin, BK; Lee, TH; Lee, YM; Oh, TH; Oh, YJ; Park, B; Park, SH; Park, YJ; Shin, DI | 1 |
13 other study(ies) available for acetylcysteine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Impairment of non-associative learning in a rat experimental model of preclinical stage of Parkinson's disease.
Topics: Acetylcysteine; Animals; Axons; Behavior, Animal; Cognitive Dysfunction; Disease Models, Animal; Dopaminergic Neurons; Humans; Learning; Mesencephalon; Parkinson Disease, Secondary; Prefrontal Cortex; Rats | 2017 |
[EFFECT OF QUERCETIN ON NEURODEGENERATIVE AND COMPENSATORY PROCESSES IN NIGROSTRIATAL SYSTEM IN A MODEL OF PRECLINICAL PARKINSON''S DISEASE STAGE IN RATS].
Topics: Acetylcysteine; Animals; Corpus Striatum; Dopaminergic Neurons; HSP70 Heat-Shock Proteins; Male; Neurodegenerative Diseases; Parkinson Disease, Secondary; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Quercetin; Rats; Rats, Wistar; Substantia Nigra | 2016 |
Exogenous protein HSP70 blocks neurodegeneration in the rat model of the clinical stage of Parkinson's disease.
Topics: Acetylcysteine; Animals; HSP70 Heat-Shock Proteins; Male; Neuroprotective Agents; Parkinson Disease, Secondary; Protease Inhibitors; Rats; Rats, Wistar | 2014 |
GDNF Overexpression from the Native Locus Reveals its Role in the Nigrostriatal Dopaminergic System Function.
Topics: Acetylcysteine; Animals; Central Nervous System; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Gene Expression Regulation, Developmental; Glial Cell Line-Derived Neurotrophic Factor; Humans; Kidney; Mice; Neostriatum; Neuroprotective Agents; Parkinson Disease, Secondary; Substantia Nigra | 2015 |
Intrastriatal transplantation of GDNF-engineered BMSCs and its neuroprotection in lactacystin-induced Parkinsonian rat model.
Topics: Acetylcysteine; Animals; Antimetabolites; Apomorphine; Behavior, Animal; Blotting, Western; Bone Marrow Transplantation; Bromodeoxyuridine; Cysteine Proteinase Inhibitors; Dopamine; Dopamine Agonists; Glial Cell Line-Derived Neurotrophic Factor; Immunohistochemistry; Neostriatum; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Tissue Engineering; Tyrosine 3-Monooxygenase | 2010 |
Novel D3 dopamine receptor-preferring agonist D-264: Evidence of neuroprotective property in Parkinson's disease animal models induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and lactacystin.
Topics: Acetylcysteine; Animals; Benzothiazoles; Biphenyl Compounds; Brain; Brain Chemistry; Brain-Derived Neurotrophic Factor; Cysteine Proteinase Inhibitors; Dopamine Agonists; Dopamine Antagonists; Enzyme-Linked Immunosorbent Assay; Glial Cell Line-Derived Neurotrophic Factor; Immunohistochemistry; Indans; Locomotion; Male; Mice; Mice, Inbred C57BL; Motor Activity; MPTP Poisoning; Neostriatum; Neuroprotective Agents; Parkinson Disease, Secondary; Piperazines; Postural Balance; Proteasome Endopeptidase Complex; Receptors, Dopamine D3; Thiazoles | 2010 |
Proteasome inhibition in medaka brain induces the features of Parkinson's disease.
Topics: Acetylcysteine; Animals; Behavior, Animal; Blotting, Western; Brain Chemistry; Cysteine Proteinase Inhibitors; Dopamine; Dyskinesia, Drug-Induced; Immunohistochemistry; Inclusion Bodies; Microscopy, Electron, Transmission; Neurons; Norepinephrine; Oryzias; Oxidopamine; Parkinson Disease, Secondary; Proteasome Inhibitors; Swimming; Sympatholytics; Ubiquitination | 2010 |
Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease.
Topics: Acetylcysteine; Animals; Behavior, Animal; Blotting, Western; Cell Count; Chromatography, High Pressure Liquid; Dopamine; Fluorescent Antibody Technique; Immunohistochemistry; Iron; Male; Mice; Mice, Inbred C57BL; Microinjections; Microscopy, Electron; Nerve Degeneration; Neurons; Neuroprotective Agents; Parkinson Disease, Secondary; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Substantia Nigra; Ubiquitin | 2010 |
Evolution of extra-nigral damage predicts behavioural deficits in a rat proteasome inhibitor model of Parkinson's disease.
Topics: Acetylcysteine; Animals; Behavior, Animal; Corpus Striatum; Cysteine Proteinase Inhibitors; Disease Models, Animal; Disease Progression; Male; Mental Disorders; Motor Activity; Parkinson Disease, Secondary; Prognosis; Proteasome Inhibitors; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2011 |
[Sleep changes during degeneration of neurons in the substantia nigra induced by inhibitor of proteasomes lactacystin in rats].
Topics: Acetylcysteine; Animals; Cysteine Proteinase Inhibitors; Dopamine; Male; Nerve Tissue Proteins; Neurons; Parkinson Disease, Secondary; Proteasome Inhibitors; Rats; Rats, Wistar; Sleep Stages; Substantia Nigra; Tyrosine 3-Monooxygenase | 2010 |
Proteasome inhibition causes nigral degeneration with inclusion bodies in rats.
Topics: Acetylcysteine; Animals; Cysteine Endopeptidases; Dopamine; Dose-Response Relationship, Drug; Inclusion Bodies; Multienzyme Complexes; Neurons; Parkinson Disease; Parkinson Disease, Secondary; Proteasome Endopeptidase Complex; Rats; Rats, Sprague-Dawley; Striatonigral Degeneration; Substantia Nigra | 2002 |
Inhibition of proteasome activity sensitizes dopamine neurons to protein alterations and oxidative stress.
Topics: Acetylcysteine; Animals; Canavanine; Cell Survival; Cells, Cultured; Cysteine Proteinase Inhibitors; Dopamine; Female; gamma-Aminobutyric Acid; Heat-Shock Response; Immunohistochemistry; Nerve Tissue Proteins; Neurons; Oxidative Stress; Parkinson Disease, Secondary; Pregnancy; Proteasome Inhibitors; Protein Folding; Rats; Rats, Sprague-Dawley | 2004 |
Oxidative modification of peroxiredoxin is associated with drug-induced apoptotic signaling in experimental models of Parkinson disease.
Topics: Acetylcysteine; Adrenergic Agents; Animals; Apoptosis; Caspase 3; Cell Line; Disease Models, Animal; Enzyme Activation; Mesencephalon; Neurons; Oxidation-Reduction; Oxidopamine; p38 Mitogen-Activated Protein Kinases; Parkinson Disease, Secondary; Peroxiredoxins; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Signal Transduction | 2008 |